Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07284979 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Study acronym: KaiNETIC-3
StatusActive, Not Recruiting
PhasePhase 3
SponsorKailera
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Enrollment target: estimated 1200 to confirmed 1270 · Study sites: 59 to 60 · Eligibility criteria expanded, about 12 words Show 3 more changesShow less
    • Enrollment target: estimated 1200 to confirmed 1270
    • Study sites: 59 to 60
    • Eligibility criteria expanded, about 12 words
  2. Trial sites expanded: 53 → 59 locationsv14
  3. Trial sites expanded: 34 → 53 locations Primary completion date: Mar 20, 2028 to Mar 2028 · Completion date: Apr 17, 2028 to Apr 2028 · Interventions: KAI-9531 (Drug), Placebo (Drug), Semaglutide (Drug) to Placebo (Drug), Ribupatide (Drug), Semaglutide (Drug) · 3 morev13 Show 6 more changesShow less
    • Primary completion date: Mar 20, 2028 to Mar 2028
    • Completion date: Apr 17, 2028 to Apr 2028
    • Interventions: KAI-9531 (Drug), Placebo (Drug), Semaglutide (Drug) to Placebo (Drug), Ribupatide (Drug), Semaglutide (Drug)
    • Secondary endpoints revised (23)
    • Study title revised
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 33 to 34v12
  5. Study sites: 32 to 33v11
  6. Trial sites expanded: 25 → 31 locationsv10
  7. Study sites: 25 to 31v9
  8. Study sites: 24 to 25v8
  9. Study sites: 20 to 24v7
  10. Study sites: 15 to 20v6
  11. Study sites: 7 to 15v5
  12. Study sites: 5 to 7v4
  13. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 5 · Start date changed from estimate of Dec 2025 to Dec 30, 2025v3 Show 2 more changesShow less
    • Study sites: 0 to 5
    • Start date changed from estimate of Dec 2025 to Dec 30, 2025
  14. Re-verified, no change to tracked fieldsv2
  15. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Kailera
7 trials monitored
See 1 trial at risk
Obesity
3,560 trials monitored
See 142 trials at risk
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
Trial Details
NCT Number NCT07284979
Lead Sponsor Kailera
Conditions Obesity
Enrollment 1,270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov